Ultraviolet A phototherapy for sclerotic skin diseases: A systematic review

Journal of the American Academy of Dermatology

Volumn 59, Issue 6, 2008, Pages 1017-1030

  Kroft, Elisabeth B M ^a   Berkhof, Nadine J G ^a   van de Kerkhof, Peter C M ^a   Gerritsen, Rianne M J P ^a   de Jong, Elke M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIMALARIAL AGENT; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; IMIQUIMOD; METHOTREXATE; PENICILLAMINE; PENICILLIN G; PSORALEN; SALAZOSULFAPYRIDINE; STEROID; VITAMIN D DERIVATIVE;

CLINICAL TRIAL; DISEASE COURSE; DRUG INDUCED DISEASE; EOSINOPHILIC FASCIITIS; ERYTHEMA; FIBROBLAST; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; INFLAMMATORY CELL; LICHEN SCLEROSUS ET ATROPHICUS; NECROBIOSIS LIPOIDICA; PHOTOAGING; PHOTOTHERAPY; POEMS SYNDROME; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; PRURITUS; REVIEW; SCLEREDEMA; SCLERODERMA; SKIN CANCER; SYSTEMATIC REVIEW; THERAPY EFFECT; ULTRAVIOLET A RADIATION; XEROSIS;

CYTOKINES; FASCIITIS; FIBROBLASTS; GRAFT VS HOST DISEASE; HUMANS; LICHEN SCLEROSUS ET ATROPHICUS; NECROBIOSIS LIPOIDICA; PORPHYRIA CUTANEA TARDA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCLERODERMA, LOCALIZED; SCLEROSIS; SKIN; SKIN DISEASES; ULTRAVIOLET THERAPY;

EID: 55949123878     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.07.042     Document Type: Review

References (90)

1. Mutzhas M.F., Holzle E., Hofmann C., and Plewig G. A new apparatus with high radiation energy between 320-460 nm: physical description and dermatological applications. J Invest Dermatol 76 (1981) 42-47
2. Dawe R.S. Ultraviolet A1 phototherapy. Br J Dermatol 148 (2003) 626-637
3. Meffert H. Phototherapy of skin diseases. Z Arztl Fortbild Qualitatssich 86 (1992) 947-950
4. Kerscher M., Dirschka T., and Volkenandt M. Treatment of localized scleroderma by UVA1 phototherapy. Lancet 346 (1995) 1166
5. Laxer R.M., and Zulian F. Localized scleroderma. Curr Opin Rheumatol 18 (2006) 606-613
6. Peterson L.S., Nelson A.M., and Su W.P. Classification of morphea (localized scleroderma). Mayo Clin Proc 70 (1995) 1068-1076
7. Jablonska S., and Blaszczyk M. Scleroderma-like disorders. Semin Cutan Med Surg 17 (1998) 65-76
8. Sapadin A.N., and Fleischmajer R. Treatment of scleroderma. Arch Dermatol 138 (2002) 99-105
9. Ayres Jr. S., and Mihan R. Is vitamin E involved in the autoimmune mechanism?. Cutis 21 (1978) 321-325
10. Dytoc M., Ting P.T., Man J., Sawyer D., and Fiorillo L. First case series on the use of imiquimod for morphea. Br J Dermatol 153 (2005) 815-820
11. Man J., and Dytoc M.T. Use of imiquimod cream 5% in the treatment of localized morphea. J Cutan Med Surg 8 (2004) 166-169
12. Uziel Y., Feldman B.M., Krafchik B.R., Yeung R.S., and Laxer R.M. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 136 (2000) 91-95
13. Hulshof M.M., Pavel S., Breedveld F.C., Dijkmans B.A., and Vermeer B.J. Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 130 (1994) 1290-1293
14. Humbert P., Dupond J.L., Agache P., Laurent R., Rochefort A., Drobacheff C., et al. Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol 73 (1993) 449-451
15. Strauss R.M., Bhushan M., and Goodfield M.J. Good response of linear scleroderma in a child to cyclosporin. Br J Dermatol 150 (2004) 790-792
16. Falanga V., and Medsger Jr. T.A. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol 126 (1990) 609-612
17. Mohrenschlager M., Jung C., Ring J., and Abeck D. Effect of penicillin G on corium thickness in linear morphea of childhood: an analysis using ultrasound technique. Pediatr Dermatol 16 (1999) 314-316
18. Wach F., Ullrich H., Schmitz G., Landthaler M., and Hein R. Treatment of severe localized scleroderma by plasmapheresis-report of three cases. Br J Dermatol 133 (1995) 605-609
19. Seyger M.M., van den Hoogen F.H., de Boo T., and de Jong E.M. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 39 (1998) 220-225
20. Seyger M.M., van den Hoogen F.H., de Mare S., van Haelst U., and de Jong E.M. A patient with a severe scleroedema diabeticorum, partially responding to low-dose methotrexate. Dermatology 198 (1999) 177-179
21. Hunzelmann N., Anders S., Fierlbeck G., Hein R., Herrmann K., Albrecht M., et al. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 36 (1997) 433-435
22. Terheyden P., Becker J.C., Lurz C., Kahaly G.J., and Brocker E.B. Treatment of scleromyxoedema with hydroxychloroquine. J Dtsch Dermatol Ges 1 (2003) 30-35
23. Czarnecki D.B., and Taft E.H. Generalized morphea successfully treated with salazopyrine. Acta Derm Venereol 62 (1982) 81-82
24. Garcia-Bustinduy M., Noda A., Sanchez R., Gonzalez de Mesa M.J., Guimera F., and Garcia-Montelongo R. PUVA therapy in localized scleroderma. J Eur Acad Dermatol Venereol 10 (1998) 283-284
25. Kreuter A., Hyun J., Stucker M., Sommer A., Altmeyer P., and Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 54 (2006) 440-447
26. Zachariae H., Bjerring P., Halkier-Sorensen L., Heickendorff L., and Sondergaard K. Skin scoring in systemic sclerosis: a modification-relations to subtypes and the aminoterminal propeptide of type III procollagen (PIIINP). Acta Derm Venereol 74 (1994) 444-446
27. Stege H., Berneburg M., Humke S., Klammer M., Grewe M., Grether-Beck S., et al. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 36 (1997) 938-944
28. Gruss C., Stucker M., Von Kobyletzki G., Schreiber D., Altmeyer P., and Kerscher M. Low dose UVA1 phototherapy in disabling pansclerotic morphea of childhood. Br J Dermatol 136 (1997) 293-294
29. Kerscher M., Volkenandt M., Gruss C., Reuther T., Von K.G., Freitag M., et al. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 38 (1998) 21-26
30. Camacho N.R., Sanchez J.E., Martin R.F., Gonzalez J.R., and Sanchez J.L. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol 45 (2001) 697-699
31. de Rie M.A., Enomoto D.N., de Vries H.J., and Bos J.D. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. Dermatology 207 (2003) 298-301
32. Kreuter A., Jansen T., Stucker M., Herde M., Hoffmann K., Altmeyer P., et al. Low-dose ultraviolet-A1 phototherapy for lichen sclerosus et atrophicus. Clin Exp Dermatol 26 (2001) 30-32
33. El-Mofty M., Zaher H., Bosseila M., Yousef R., and Saad B. Low-dose broad-band UVA in morphea using a new method for evaluation. Photodermatol Photoimmunol Photomed 16 (2000) 43-49
34. El-Mofty M., Mostafa W., Esmat S., Youssef R., Bousseila M., Nagi N., et al. Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study. Photodermatol Photoimmunol Photomed 20 (2004) 93-100
35. El-Mofty M., Mostafa W., El-Darouty M., Bosseila M., Nada H., Yousef R., et al. Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. Photodermatol Photoimmunol Photomed 20 (2004) 148-156
36. Oikarinen A., and Knuutinen A. Ultraviolet A sunbed used for the treatment of scleroderma. Acta Derm Venereol 81 (2001) 432-433
37. Gruss C.J., Von Kobyletzki G., Behrens-Williams S.C., Lininger J., Reuther T., Kerscher M., et al. Effects of low dose ultraviolet A-1 phototherapy on morphea. Photodermatol Photoimmunol Photomed 17 (2001) 149-155
38. Steger J.W., and Matthews J.H. UVA therapy for scleroderma. J Am Acad Dermatol 40 (1999) 787-788
39. Yildirim M., Baysal V., Aridogan B.C., Kesici D., and Erturan I. Pansclerotic morphea treated with UVA: a case report. J Dermatol 30 (2003) 625-627
40. Breuckmann F., Avermaete A., Kreuter A., Altmeyer P., and von Kobyletzki G. Indications for UVA1 phototherapy: an update. Photodermatol Photoimmunol Photomed 17 (2001) 83
41. Tuffanelli D.L. Localized scleroderma. Semin Cutan Med Surg 17 (1998) 27-33
42. Kreuter A., Gambichler T., Avermaete A., Happe M., Bacharach-Buhles M., Hoffmann K., et al. Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study. J Am Acad Dermatol 46 (2002) 251-255
43. Beattie P.E., Dawe R.S., Ferguson J., and Ibbotson S.H. UVA1 phototherapy for genital lichen sclerosus. Clin Exp Dermatol 31 (2006) 343-347
44. Bhushan V., and Collins Jr. R.H. Chronic graft-vs-host disease. JAMA 290 (2003) 2599-2603
45. Grundmann-Kollmann M., Behrens S., Gruss C., Gottlober P., Peter R.U., and Kerscher M. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 42 (2000) 134-136
46. Wetzig T., Sticherling M., Simon J.C., Hegenbart U., Niederwieser D., and Al-Ali H.K. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 35 (2005) 515-519
47. Ständer H., Schiller M., and Schwarz T. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol 46 (2002) 799-800
48. Calzavara P.P., Porta F., Izzi T., Venturini M., Capezzera R., Zane C., and Notarangelo L.D. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica 88 (2003) 1169-1175
49. Janiga J.J., Ward D.H., and Lim H.W. UVA-1 as a treatment for scleredema. Photodermatol Photoimmunol Photomed 20 (2004) 210-211
50. Eberlein-Konig B., Vogel M., Katzer K., Hein R., Kohn F.M., Ring J., et al. Successful UVA1 phototherapy in a patient with scleredema adultorum. J Eur Acad Dermatol Venereol 19 (2005) 203-204
51. Tuchinda C., Kerr H.A., Taylor C.R., Jacobe H., Bergamo B.M., Elmets C., et al. UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol Photoimmunol Photomed 22 (2006) 247-253
52. Beattie P.E., Dawe R.S., Ibbotson S.H., and Ferguson J. UVA1 phototherapy for treatment of necrobiosis lipoidica. Clin Exp Dermatol 31 (2006) 235-238
53. Behrens S., Reuther T., Von K.G., Kastner U., Dirschka T., and Kerscher M. Bleomycin-induced PSS-like pseudoscleroderma: case report and review of the literature. Hautarzt 49 (1998) 725-729
54. Karamfilov T., Buslau M., Dürr C., and Weyers W. Pansclerotic porphyria cutanea tarda after chronic exposure to organic solvents. Hautarzt 54 (2003) 448-452
55. Schaller M., Romiti R., Wollenberg A., Prinz B., and Woerle B. Improvement of cutaneous manifestations in POEMS syndrome after UVA1 phototherapy. J Am Acad Dermatol 45 (2001) 969-970
56. Grewe M., Gyufko K., and Krutmann J. Interleukin-10 production by cultured human keratinocytes: regulation by ultraviolet B and ultraviolet A1 radiation. J Invest Dermatol 104 (1995) 3-6
57. Grabbe J., Welker P., Humke S., Grewe M., Schopf E., Henz B.M., et al. High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J Invest Dermatol 107 (1996) 419-422
58. Morita A., Werfel T., Stege H., Ahrens C., Karmann K., Grewe M., et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 186 (1997) 1763-1768
59. Breuckmann F., Pieck C., Kreuter A., Bacharach-Buhles M., Mannherz H.G., Altmeyer P., et al. Opposing effects of UVA1 phototherapy on the expression of bcl-2 and p53 in atopic dermatitis. Arch Dermatol Res 293 (2001) 178-183
60. Gruss C., Reed J.A., Altmeyer P., McNutt N.S., and Kerscher M. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 350 (1997) 1295-1296
61. Scharffetter K., Wlaschek M., Hogg A., Bolsen K., Schothorst A., Goerz G., et al. UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 283 (1991) 506-511
62. Petersen M.J., Hansen C., and Craig S. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol 99 (1992) 440-444
63. Johnston K.J., Oikarinen A.I., Lowe N.J., Clark J.G., and Uitto J. Ultraviolet radiation-induced connective tissue changes in the skin of hairless mice. J Invest Dermatol 82 (1984) 587-590
64. Oikarinen A., Karvonen J., Uitto J., and Hannuksela M. Connective tissue alterations in skin exposed to natural and therapeutic UV-radiation. Photodermatology 2 (1985) 15-26
65. Sakura S., Fujimoto D., Sakamoto K., Mizuno A., and Motegi K. Photolysis of pyridinoline, a cross-linking amino acid of collagen, by ultraviolet light. Can J Biochem 60 (1982) 525-529
66. Fisher G.J., Datta S.C., Talwar H.S., Wang Z.Q., Varani J., Kang S., et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature 379 (1996) 335-339
67. Fisher G.J., and Kang S. Phototherapy for scleroderma: biologic rationale, results, and promise. Curr Opin Rheumatol 14 (2002) 723-726
68. Petersen M., Hamilton T., and Li H.L. Regulation and inhibition of collagenase expression by long-wavelength ultraviolet radiation in cultured human skin fibroblasts. Photochem Photobiol 62 (1995) 444-448
69. Wlaschek M., Wenk J., Brenneisen P., Briviba K., Schwarz A., Sies H., et al. Singlet oxygen is an early intermediate in cytokine-dependent ultraviolet-A induction of interstitial collagenase in human dermal fibroblasts in vitro. FEBS Lett 413 (1997) 239-242
70. Brenneisen P., Briviba K., Wlaschek M., Wenk J., and Scharffetter-Kochanek K. Hydrogen peroxide (H2O2) increases the steady-state mRNA levels of collagenase/MMP-1 in human dermal fibroblasts. Free Radic Biol Med 22 (1997) 515-524
71. Kiss M., Wlaschek M., Brenneisen P., Michel G., Hommel C., Lange T.S., et al. Alpha-melanocyte stimulating hormone induces collagenase/matrix metalloproteinase-1 in human dermal fibroblasts. Biol Chem Hoppe Seyler 376 (1995) 425-430
72. Duncan M.R., and Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 97 (1991) 686-692
73. Kreuter A., Hyun J., Skrygan M., Sommer A., Bastian A., Altmeyer P., et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol 155 (2006) 600-607
74. Kreuter A., Hyun J., Skrygan M., Sommer A., Tomi N.S., Breuckmann F., et al. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma. Arch Dermatol Res 298 (2006) 265-272
75. Mori Y., Chen S.J., and Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 48 (2003) 1964-1978
76. Edwards D.R., Murphy G., Reynolds J.J., Whitham S.E., Docherty A.J., Angel P., et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 6 (1987) 1899-1904
77. Dong C., Zhu S., Wang T., Yoon W., Li Z., Alvarez R.J., et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 99 (2002) 3908-3913
78. Moustakas A., Souchelnytskyi S., and Heldin C.H. Smad regulation in TGF-beta signal transduction. J Cell Sci 114 (2001) 4359-4369
79. + spindle-shaped cells selectively disappear from the skin lesion of scleroderma. Arch Dermatol 130 (1994) 593-597
80. Skobieranda K., and Helm K.F. Decreased expression of the human progenitor cell antigen (CD34) in morphea. Am J Dermatopathol 17 (1995) 471-475
81. Sacher C., Konig C., Scharffetter-Kochanek K., Krieg T., and Hunzelmann N. Bullous pemphigoid in a patient treated with UVA-1 phototherapy for disseminated morphea. Dermatology 202 (2001) 54-57
82. Lee C.W., and Ro Y.S. Sun-induced localized bullous pemphigoid. Br J Dermatol 126 (1992) 91-92
83. Perl S., Rappersberger K., Fodinger D., Anegg B., Honigsmann H., and Ortel B. Bullous pemphigoid induced by PUVA therapy. Dermatology 193 (1996) 245-247
84. Pfau A., Hohenleutner U., Hohenleutner S., Eckert F., and Landthaler M. UV-A-provoked localized bullous pemphigoid. Acta Derm Venereol 74 (1994) 314-316
85. Thomsen K., and Schmidt H. PUVA-induced bullous pemphigoid. Br J Dermatol 95 (1976) 568-569
86. Breuckmann F., Gambichler T., Altmeyer P., and Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol 4 (2004) 11
87. Krutmann J., Czech W., Diepgen T., Niedner R., Kapp A., and Schopf E. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 26 (1992) 225-230
88. Breuckmann F., Von Kobyletzki G., Avermaete A., Kreuter A., Mannherz H.G., and Altmeyer P. Apoptosis of human dermal endothelial cells as a potential side effect following therapeutic administration of UVA1 irradiation: preliminary results. Arch Dermatol Res 294 (2002) 303-309
89. Runger T.M. Role of UVA in the pathogenesis of melanoma and non-melanoma skin cancer: a short review. Photodermatol Photoimmunol Photomed 15 (1999) 212-216
90. Sterenborg H.J., and van der Leun J.C. Tumorigenesis by a long wavelength UV-A source. Photochem Photobiol 51 (1990) 325-330